Initiated combination portion of Phase 1 clinical trial of QTX3046, an oral KRASG12D-selective dual ON/OFF state allosteric inhibitor, with the EGFR inhibitor cetuximab – – Phase 1 clinical trial of ...

QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 7 ...

QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase tra ...

Acellera Therapeutics, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of ...

Quantum eMotion (TSXV: QNC) (OTCQB: QNCCF) (QeM) recently announced the commercialization of its quantum-powered security ...

Keep an eye on the first patient dosed in phase 1 and 2 trials of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD),with ...

Acellera Therapeutics, a pioneer in computational ... model designed to deliver quantum-level accuracy for predicting atomic interactions—an essential factor in identifying promising drug ...

Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor: Radnor, Pennsylvania Friday, January 10, 2025 ...

As the digital therapeutics field continues to revolutionize healthcare ... QeM has become a pioneering force in classical and quantum cybersecurity solutions thanks to its patented Quantum Random ...

As the digital therapeutics field continues to revolutionize ... and scalability across diverse healthcare systems. About QeM ( %Quantum eMotion Corp.) The Company aims to address the growing ...

Quantum Emotion Corp. (V.QNC) hit a new 52-week high of $1.44 Monday. Quantum eMotion recently announced the commercialization of its quantum-powered security platform, Sentry-Q, designed to fortify ...